Tykerb/Herceptin Combination Will Go Before FDA Advisory Panel

FDA’s Oncologic Drugs Advisory Committee will review a combination of GlaxoSmithKline’s Tykerb (lapatinib) with Roche’s Herceptin (trastuzumab) that would offer patients with HER-2 positive metastatic breast cancer a chemo-free option.